CAMRIS Participates in Army’s Vaccine Research
BETHESDA, Md.--(BUSINESS WIRE)--Jan 6, 2022--
CAMRIS International, LLC, an HJF Company, today announced its involvement in COVID-19 vaccine research by the Walter Reed Army Institute of Research (WRAIR).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005762/en/
The Pilot Bioproduction Facility (PBF) is a cGMP-compliant pharmaceutical manufacturing facility located in Silver Spring, MD, at the Walter Reed Army Institute of Research. The PBF completed extensive renovations in 2020. (U.S. Army photo by Mike Walter)
As recently reported in a leading scientific journal, the Army’s development of a COVID-19 vaccine using a Spike Ferritin Nanoparticle (SpFN) platform showed encouraging preclinical results. Also, as reported in The Hill, the developed vaccine may also have broader effectiveness against SARS-origin viruses and emerging variants. That SpFN platform is manufactured in WRAIR’s Pilot Bioproduction Facility (PBF) in Silver Spring, MD. The PBF is the only cGMP-compliant pharmaceutical manufacturing plant in the U.S. Army and the Department of Defense.
CAMRIS currently supports operation of the WRAIR PBF under an Other Transaction Authority type agreement and is a key manufacturing partner. “CAMRIS is particularly proud to support WRAIR’s Pilot Bioproduction Facility in combatting the scourge of COVID-19,” said Brad Sepp, MS, CAMRIS’ Vice President of Programs and Pilot Bioproduction Facility Program Manager.
CAMRIS is an innovative federal government contractor in the fields of military health and research, international development, global health, and clinical and life sciences with over 60 years of experience in over 100 countries.
View source version on businesswire.com:https://www.businesswire.com/news/home/20220106005762/en/
Please direct any media inquiries to Brad Sepp:firstname.lastname@example.org
KEYWORD: MARYLAND UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: RESEARCH OTHER DEFENSE INFECTIOUS DISEASES PUBLIC POLICY/GOVERNMENT BIOTECHNOLOGY WHITE HOUSE/FEDERAL GOVERNMENT HEALTH SCIENCE DEFENSE
SOURCE: CAMRIS International, LLC
Copyright Business Wire 2022.
PUB: 01/06/2022 12:29 PM/DISC: 01/06/2022 12:29 PM